Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
INTRODUCTION AND OBJECTIVE: Serous retinopathy can be associated with MEK inhibitors, including cobimetinib. We present results of an integrated safety analysis to further characterize ocular functional and structural changes due to serous retinopathy. METHODS: Four studies evaluating cobimetinib at the approved dose and schedule in combination with other oncology drugs were included. Study CO39721 incorporated standardized ophthalmologic assessments to fully characterize serous retinopathy events over time and was the primary study for analysis. Supporting information was provided by studies GO28141, WO29479, and GO30182. RESULTS: In total, 655 patients received one or more doses of cobimetinib and comprised the safety-evaluable population. Overall, 117 patients (17.9%) had one or more serous retinopathy events, 24 (3.7%) had two or more events, and four (0.6%) had three or more events. Grade 3 events occurred in < 2.5% of patients. In CO39721, the median time to onset was 15 days (range 7-111); median time to resolution of first occurrence was 26 days (range 6-591 + days). Twelve of 25 patients (48.0%) recovered without a dose modification and 4/25 (16.0%) were recovered/recovering following a dose modification. The most frequent presentation of serous retinopathy was focal subretinal fluid on optical coherence tomography (62.8% of cases); in some instances (25.7% of cases), subretinal fluid was multifocal. There was no loss of visual function or visual acuity at serous retinopathy onset or resolution. CONCLUSIONS: Results from this integrated safety analysis indicate that cobimetinib-associated serous retinopathy can be managed with or without a dose modification of cobimetinib at the discretion of the treating physician. No visual loss or permanent retinal damage was identified on comprehensive ophthalmologic assessments. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03178851, NCT01689519, NCT02322814, and NCT02788279.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These effects seem to be function-specific to the MEK inhibition itself and not compound side-effects from alternative actions, as the same clinical observations with the same levels of MEKAR severity have been also observed in patients receiving pimasertib [ 222 ] or cobimetinib (a MEK inhibitor), which was manageable in the latter case even without a dose modification, and with no visual loss or”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [223]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577 · cited 1×
“Finally, GO30182 (COTEZO; NCT02788279) was a phase III, multicenter, randomized, open-label study evaluating cobimetinib in combination with atezolizumab in patients with previously untreated, advanced colorectal cancer [18].”
BackgroundInfante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Risk Factors for Incident Retinopathy in a Diabetic and Nondiabetic Population: The Hoorn Study
van Leiden, H. A. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.2.245 · Cited by 265
RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis
Liu, B., Deng, T., & Zhang, J. (2016) · Retina · doi:10.1097/iae.0000000000000837 · Cited by 213
The MEK/ERK Network as a Therapeutic Target in Human Cancer
Barbosa, R., Acevedo, L. A., & Marmorstein, R. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0687 · Cited by 210
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Francis, J. H., Habib, L. A., Abramson, D. H., Yannuzzi, L. A., Heinemann, M., Gounder, M. M., Grisham, R. N., Postow, M. A., Shoushtari, A. N., Chi, P., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.038 · Cited by 141
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“These effects seem to be function-specific to the MEK inhibition itself and not compound side-effects from alternative actions, as the same clinical observations with the same levels of MEKAR severity have been also observed in patients receiving pimasertib [222] or cobimetinib (a MEK inhibitor), which was manageable…”
ResultCobimetinib-related serous retinopathy
(2022) · Reactions Weekly · doi:10.1007/s40278-022-27375-1
Adamski, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188244
Metadata
- Authors
- Barteselli, G., Goodman, G. R., Patel, Y., Caro, I., Xue, C., & McCallum, S.
- Affiliations
- Roche (United States) (US)
- Roche (United Kingdom) (GB)
- Roche (Canada) (CA)
- Corresponding author
- McCallum, Samuel
- Venue
- Drug Safety
- Published
- 2022-10-30
- Volume
- 45
- Issue
- 12
- Pages
- 1491-1499
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- PMC
- PMC9700562
- OpenAlex
- W4307642528
- Cited by
- 4
- References
- 28
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 1
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drug Safety (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- F. Hoffmann-La Roche Ltd
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- cobimetinib, MEK inhibitors, drug-induced ocular toxicity, subretinal fluid, dose adjustment, visual acuity, integrated safety analysis
- MeSH terms
- Azetidines, Humans, Piperidines, Retinal Diseases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. https://app.cochat.ai/papers/10.1007/s40264-022-01248-2
- The paper
- Barteselli, G., Goodman, G. R., Patel, Y., Caro, I., Xue, C., & McCallum, S. (2022). Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Safety. https://doi.org/10.1007/s40264-022-01248-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.